HK1212250A1 - Antiviral compounds, unit dosage form comprising said compounds and use thereof - Google Patents

Antiviral compounds, unit dosage form comprising said compounds and use thereof Download PDF

Info

Publication number
HK1212250A1
HK1212250A1 HK16100369.5A HK16100369A HK1212250A1 HK 1212250 A1 HK1212250 A1 HK 1212250A1 HK 16100369 A HK16100369 A HK 16100369A HK 1212250 A1 HK1212250 A1 HK 1212250A1
Authority
HK
Hong Kong
Prior art keywords
compound
virus
formula
certain embodiments
dosage form
Prior art date
Application number
HK16100369.5A
Other languages
English (en)
Chinese (zh)
Inventor
Sudhakara Babu Yarlagadda
Chand Pooran
Bantia Shanta
Arnold Shane
Michael Kilpatrick John
Original Assignee
Biocryst Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38169715&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1212250(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2006/013535 external-priority patent/WO2007117241A1/en
Application filed by Biocryst Pharmaceuticals, Inc. filed Critical Biocryst Pharmaceuticals, Inc.
Publication of HK1212250A1 publication Critical patent/HK1212250A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK16100369.5A 2006-02-13 2016-01-14 Antiviral compounds, unit dosage form comprising said compounds and use thereof HK1212250A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US77274806P 2006-02-13 2006-02-13
US60/772748 2006-02-13
USPCT/US2006/013535 2006-04-12
PCT/US2006/013535 WO2007117241A1 (en) 2006-04-12 2006-04-12 Intramuscular antiviral treatments

Publications (1)

Publication Number Publication Date
HK1212250A1 true HK1212250A1 (en) 2016-06-10

Family

ID=38169715

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16100369.5A HK1212250A1 (en) 2006-02-13 2016-01-14 Antiviral compounds, unit dosage form comprising said compounds and use thereof

Country Status (11)

Country Link
EP (1) EP1986626A1 (enExample)
JP (3) JP2009538822A (enExample)
KR (9) KR102323339B1 (enExample)
AU (2) AU2007215156A1 (enExample)
BR (1) BRPI0707769A2 (enExample)
CA (1) CA2642260C (enExample)
EA (1) EA025483B1 (enExample)
HK (1) HK1212250A1 (enExample)
MX (2) MX393640B (enExample)
MY (1) MY166063A (enExample)
WO (1) WO2007095218A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102323339B1 (ko) * 2006-02-13 2021-11-08 바이오크리스트 파마수티컬즈, 인코퍼레이티드 정맥내 항바이러스 치료
CN101367750B (zh) * 2007-08-14 2012-05-23 中国人民解放军军事医学科学院毒物药物研究所 (1s,2s,3s,4r)-3-[(1s)-1-乙酰氨-2-乙基-丁基]-4-胍基-2-羟基-环戊基-1-羧酸水合物及其医药用途
KR20220033561A (ko) 2020-09-07 2022-03-17 주식회사 경보제약 페라미비르 화합물을 포함하는 프리믹스 제형의 제약학적 조성물

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2263179T3 (es) * 1996-06-14 2006-12-01 Biocryst Pharmaceuticals Inc. Compuestos de clopentano sustituido como inhibidores de la neuraminidasa.
BR9813480A (pt) * 1997-12-17 2000-10-10 Biocryst Pharm Inc Compostos inibidores de neuraminidase de ciclopentano substituìdo, composição e métodos de inibição da neuraminidase do vìrus da influenza- e de tratamento de infecção por vìrus da influenza-
GB0015324D0 (en) * 2000-06-22 2000-08-16 Biota Scient Management Medicaments
KR102323339B1 (ko) * 2006-02-13 2021-11-08 바이오크리스트 파마수티컬즈, 인코퍼레이티드 정맥내 항바이러스 치료

Also Published As

Publication number Publication date
BRPI0707769A2 (pt) 2011-05-10
CA2642260A1 (en) 2007-08-23
KR102267754B1 (ko) 2021-06-23
KR102323339B1 (ko) 2021-11-08
KR20200143519A (ko) 2020-12-23
KR20210135632A (ko) 2021-11-15
MX393640B (es) 2025-03-21
EP1986626A1 (en) 2008-11-05
KR101992585B9 (ko) 2022-09-20
KR102475176B1 (ko) 2022-12-07
KR102194015B1 (ko) 2020-12-22
MX2008010394A (es) 2009-01-12
WO2007095218A1 (en) 2007-08-23
KR20160129105A (ko) 2016-11-08
KR20080096829A (ko) 2008-11-03
AU2013216632A1 (en) 2013-08-29
AU2013216632B2 (en) 2016-09-01
KR20140132778A (ko) 2014-11-18
CA2642260C (en) 2016-08-09
KR101992585B1 (ko) 2019-06-25
JP2015180695A (ja) 2015-10-15
KR20180024027A (ko) 2018-03-07
KR20210076189A (ko) 2021-06-23
JP6073202B2 (ja) 2017-02-01
EA200870263A1 (ru) 2009-06-30
EA025483B1 (ru) 2016-12-30
KR20230003248A (ko) 2023-01-05
MY166063A (en) 2018-05-23
KR20190072681A (ko) 2019-06-25
AU2007215156A1 (en) 2007-08-23
MX2020002008A (es) 2020-07-13
JP2013256527A (ja) 2013-12-26
JP2009538822A (ja) 2009-11-12

Similar Documents

Publication Publication Date Title
US12121503B2 (en) Antiviral treatments
HK1212250A1 (en) Antiviral compounds, unit dosage form comprising said compounds and use thereof
CN104784166A (zh) 抗病毒化合物、包含该化合物的剂型及其用途
AU2016262644B2 (en) Intravenous antiviral treatments
JP2009538822A5 (enExample)
NZ570538A (en) Intravenous antiviral treatments
US20070244193A1 (en) Intramuscular antiviral treatments
KR20080113099A (ko) 근육내 항바이러스 치료